Nulibry obtains FDA approval weeks ahead of its action date. Although small patient base offers modest revenue opportunity, approval enables BridgeBio to get commercial operations underway.

Germany’s Merck has licensed exclusive rights to develop and sell Debiopharm’s potential first-in-class inhibitor of apoptosis proteins (IAP) antagonist, targeting head and neck cancers.

Key committee was asked to fast-track a decision on the antibody cocktail, but lack of mortality data could mean patchy uptake seen in US repeated in the EU.

If demand-side pressures on the life science sector were not enough, generic price erosion, debt repayment and extended restructurings are worsening the generic pharmaceutical investment proposition.

Like most CEOs in pharma, Bayer chief Werner Baumann was constantly on the move but "since the middle to the end of the first quarter last year, I haven't traveled at all."

As Takeda pays down debt associated with the acquisition of Shire and advances R&D programs toward global filings, the company is selling its growth plan to investors – but are they buying?

Germany’s Merck has licensed exclusive rights to develop and sell Debiopharm’s potential first-in-class inhibitor of apoptosis proteins (IAP) antagonist, targeting head and neck cancers.

The firms' messenger RNA alliance inked back on 2013 is still very much ongoing but AstraZeneca decided to sell its considerable stake in the high-profile biotech to help finance its own pipeline.

Looking back at the deal landscape of 2020, large-scale deals were overtaken by smaller transactions, though volume was up, driven by pandemic-related business.

Merck & Co. reached a deal to acquire the developer of targeted immune modulators for $1.85bn. Pandion CEO Kakkar talked to Scrip about the acquisition.

CEO Werner Baumann admits he was skeptical at first as to whether the German group had the necessary know-how to manufacture vaccines but the firm's expertise in the development of biotech products has strengthened his belief Bayer can deliver.

Two European pharmaceutical companies, UCB and Merck KGaA, are exploring artificial intelligence in different ways, the first for drug discovery and the second on a fundamental level.

The firms' messenger RNA alliance inked back on 2013 is still very much ongoing but AstraZeneca decided to sell its considerable stake in the high-profile biotech to help finance its own pipeline.

Like most CEOs in pharma, Bayer chief Werner Baumann was constantly on the move but "since the middle to the end of the first quarter last year, I haven't traveled at all."

Novartis and Takeda’s R&D efforts saw an impact from the COVID-19 pandemic, but both Lutz Hegemann and Andrew Plump believe that when the next pandemic hits, the industry and regulators will be better prepared for it.

Following positive interim results from a Phase I/IIa trial of BI-1206 in combination with Roche's Rituxan, BioInvent has raised a significant sum to push the non-Hodgkin's lymphoma drug towards late-stage development.

The Belgian biotech is pleased with the launch of its rheumatoid arthritis drug in Germany and the Netherlands and it has also secured a broad label from NICE.

Following a trio of high-profile setbacks, the Belgian biotech is looking to fill the gap between the European launches of its rheumatoid arthritis drug Jyseleca and its programs back in Phase II via in-licensing and M&A.

The Belgian biotech is pleased with the launch of its rheumatoid arthritis drug in Germany and the Netherlands and it has also secured a broad label from NICE.

The Swiss major envisions developing an accessible in vivo gene therapy for SCD that could potentially be administered once directly to the patient without the need to modify cells in a lab.

Rheumatologists may be more cautious about prescribing biosimilars to Humira than they have been for biosimilars to Avastin and Herceptin. But pharmacy benefit managers will have more influence over Humira biosimilars, which adds a new dynamic to the follow-on market.

Around 100 executives highlight the hot areas to watch on the R&D front in 2021. From cancer to CNS and from regenerative medicine to real world data, expectations are high on many fronts.

Executives expect the changes wrought by necessity in the face of a global pandemic to have lasting effects, both positive and negative, on the biopharma sector. Here they share their predictions for the coming year.

Roche’s first-in-class one-dose antiviral Xofluza has been approved for marketing in the EU to treat influenza in patients aged 12 years or over, and for post-exposure prophylaxis.